Aligos Therapeutics, Inc.

ALGS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$31,537-$15,863$43,088-$82,150
Dep. & Amort.$220$259$510$671
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$1,160$959$1,705
Change in WC$1,532$930-$3,835-$390
Other Non-Cash$5,440-$1,990-$61,631$61,761
Operating Cash Flow-$24,345-$15,504-$20,909-$18,403
Investing Activities
PP&E Inv.-$193-$109-$43-$28
Net Acquisitions$0$0$0$0
Inv. Purchases-$22,124-$39,312-$64,024$0
Inv. Sales/Matur.$70,000$0$20,000$20,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$47,683-$39,421-$44,067$19,972
Financing Activities
Debt Repay.-$10-$1$0-$43
Stock Issued-$43-$176$101,742$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$140
Financing Cash Flow-$53-$177$101,742$97
Forex Effect$0$0$0$0
Net Chg. in Cash$23,285-$55,102$36,766$1,666
Supplemental Information
Beg. Cash$18,771$73,873$37,107$35,441
End Cash$42,056$18,771$73,873$37,107
Free Cash Flow-$24,538-$15,613-$20,952-$18,431